Antineoplastons are a group of naturally-occurring peptides and amino acid derivatives which control tumor growth, and have been proven in clinical studies on a number of advanced cancer cases to be highly effective and non-toxic, relative to chemotherapy.
First identified by Dr. Stanislaw Burzynski in human blood in 1967, he observed "[T]here were significant differences in the peptide content in the serum of cancer patients as compared with the control group."
Owing to the fact that similar peptide fractions are found in human urine and can be purified as a bulk source of antineoplastons, Dr. Burzynski began a research program "for the identification of antineoplastic peptides from urine" known as the Burzynski Research Institute (BRI), which was incorporated under the laws of the State of Delaware in 1984.[i]
The discovery that urine contains therapeutic compounds is not novel. According to Dr. Burzynski:
"Medicinal use of urine and urine extracts has been known for centuries in ancient Egypt, Greece, Rome, India and North and Central America. In modern times, the first study of growth-inhibiting substances in urine was conducted in 1937. The research on urinary peptides has a long history and was initiated by a Polish researcher, S. Bondzynski, in 1897."[ii]
Dr. Burzyinski’s research lead to the discovery of five different peptide fractions which he named Antineoplaston A1, A2, A3, A4 and A5. The first active component was identified as 3-phenylacetylamino-2,6-piperidinedione and was named Antineoplaston A10. Two synthetic derivatives of Antineoplaston A10 were named Antineoplaston AS2-1 and Antineoplaston AS2-5.
GreenMedInfo.com has done an exhaustive index of the research on the topic as found on the National Library of Medicine, which can be found below.
Latest topical blog Antineoplastons: A Cure for Cancer Ignored For 45 Years?